间歇性禁食通过降低Lrg1的调节来改善MAFLD:来自大量RNA测序和功能验证的见解
Huafeng Chen1, Shilin Zhang1, Wenqiang Xie1
1Department of Endocrinology and Metabolism, The Eighth Affiliated Hospital, Southern Medical University (The First People's Hospital of Shunde, Foshan), Foshan, Guangdong, China.
Frontiers in endocrinology
|March 4, 2026
概括
间歇性禁食 (IF) 通过调节脂肪酸代谢和炎症来改善与代谢功能障碍相关的脂肪肝疾病 (MAFLD). 击败一个关键基因Lrg1,通过抑制脂原基因表达来减缓MAFLD的进展.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢障碍 代谢障碍 代谢障碍
- 基因组学就是基因组学.
背景情况:
- 与代谢功能障碍相关的脂肪肝疾病 (MAFLD) 的患病率在全球范围内正在上升.
- 目前的MAFLD治疗方法有局限性.
- 研究间歇性禁食 (IF) 作为MAFLD的潜在治疗策略.
研究的目的:
- 为了研究间歇性禁食 (IF) 对MAFLD的影响.
- 阐明在MAFLD中IF的潜在分子机制.
主要方法:
- 从不同饮食和禁食条件下的小鼠肝脏组织的散装RNA测序.
- 不同基因表达分析,基因本体学 (GO),基因和基因组的京都百科全书 (KEGG) 和基因组丰富分析 (GSEA).
- 权重基因共同表达网络分析 (WGCNA),蛋白与蛋白相互作用 (PPI) 网络分析,以及RT-qPCR用于关键基因验证.
主要成果:
- 在MAFLD小鼠中,IF显著改善了代谢异常和减少了肝脂沉积.
- 转录组分析确定了富含脂肪酸代谢和炎症反应途径的差异表达基因 (DEG).
- Lrg1被确定为一个关键基因;通过PI3K-AKT通路,其敲击抑制了脂原基因表达 (Srebf1,Scd1,Fasn),减缓了MAFLD的进展.
结论:
- 间歇性禁食通过调节脂肪酸代谢和炎症途径来改善MAFLD.
- 包括Lrg1在内的关键基因在IF对MAFLD的治疗效果中起着至关重要的作用.
- 准Lrg1是一个潜在的治疗策略,可以减缓MAFLD的进展.
相关概念视频
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...


